Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Eur Urol
    August 2017
  1. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    >> Share

    July 2017
  2. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    >> Share

    June 2017
  3. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    >> Share

  4. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    >> Share

  5. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    >> Share

  6. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    >> Share

  7. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    >> Share

  8. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    >> Share

  9. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    >> Share

    May 2017
  10. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    >> Share

  11. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    >> Share

  12. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    >> Share

  13. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    >> Share

  14. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    >> Share

    April 2017
  15. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    >> Share

  16. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    >> Share

  17. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    >> Share

  18. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    >> Share

  19. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    >> Share

    March 2017
  20. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    >> Share

  21. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    >> Share

    February 2017
  22. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    >> Share

  23. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    >> Share

  24. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    >> Share

    January 2017
  25. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    >> Share

  26. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    >> Share

  27. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    >> Share

  28. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    >> Share

    December 2016
  29. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    >> Share

    October 2016
  30. LIEDBERG F, Jancke G, Sorenby A, Kannisto P, et al
    Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30713.
    >> Share

  31. NECCHI A, Giardiello D, Mariani L
    Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30684.
    >> Share

    September 2016
  32. LUO HL, Chen YT, Cheng YT, Chiang PH, et al
    Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Can
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30663.
    >> Share

  33. SEISEN T, Babjuk M, Roupret M
    Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30662.
    >> Share

    August 2016
  34. LONGO T, McGinley KF, Freedman JA, Etienne W, et al
    Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.
    Eur Urol. 2016 Aug 9. pii: S0302-2838(16)30463.
    >> Share

    July 2016
  35. SEISEN T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, et al
    Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephrourecterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
    Eur Urol. 2016 Jul 28. pii: S0302-2838(16)30419.
    >> Share

  36. ARENDS TJ, Witjes JA
    Reply to Slawomir Poletajew, Piotr Radziszewski, Juan Palou Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Baci
    Eur Urol. 2016 Jul 14. pii: S0302-2838(16)30395.
    >> Share

  37. POLETAJEW S, Radziszewski P, Palou J
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30394.
    >> Share

  38. BABJUK M
    Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30392.
    >> Share

  39. YANG Z, Li C, Liu H, Zhang X, et al
    Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells.
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30343.
    >> Share

  40. YOSSEPOWITCH O
    Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
    Eur Urol. 2016;70:204.
    >> Share

    June 2016
  41. ALFRED WITJES J, Lebret T, Comperat EM, Cowan NC, et al
    Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
    Eur Urol. 2016 Jun 30. pii: S0302-2838(16)30290.
    >> Share

  42. ANTONI S, Ferlay J, Soerjomataram I, Znaor A, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2016 Jun 28. pii: S0302-2838(16)30280.
    >> Share

  43. HERMANS TJ, Mertens LS, van Rhijn BW
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides.
    Eur Urol. 2016;69:1156-7.
    >> Share

    May 2016
  44. MCKIERNAN J
    Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer: One Size Does Not Fit All.
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30033.
    >> Share

  45. WITJES JA
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides.
    Eur Urol. 2016;69:963.
    >> Share

    April 2016
  46. CUMBERBATCH MG, Catto JW
    Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?
    Eur Urol. 2016 Apr 29. pii: S0302-2838(16)30066.
    >> Share

  47. NAITO S, Algaba F, Babjuk M, Bryan RT, et al
    The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Mus
    Eur Urol. 2016 Apr 22. pii: S0302-2838(16)30031.
    >> Share

  48. GRAY PJ, Efstathiou JA, Shipley WU
    Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.
    Eur Urol. 2016;69:757-8.
    >> Share

  49. PICKARD R
    Is Robot-assisted Cystectomy Better than Open?--Nearing an Answer after a Decade of Use.
    Eur Urol. 2016;69:622-3.
    >> Share

  50. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    >> Share

    March 2016
  51. GUO CC, Dadhania V, Zhang L, Majewski T, et al
    Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Eur Urol. 2016 Mar 14. pii: S0302-2838(16)00246.
    >> Share

  52. RENTSCH CA, Muller DC, Ruiz C, Bubendorf L, et al
    Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer.
    Eur Urol. 2016 Mar 4. pii: S0302-2838(16)00240.
    >> Share

  53. ROUPRET M
    Re: Finasteride Reduces the Risk of Bladder Cancer in a Large Prospective Screening Study.
    Eur Urol. 2016;69:537.
    >> Share

  54. SHIBING Y, Qiang W
    Re: Morgan Roupret, Marko Babjuk, Eva Comperat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Eur Urol. 2016;69:e49-50.
    >> Share

  55. ROUPRET M
    Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Roupret, Marko Babjuk, Eva Comperat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Eur Urol. 2016;69:e51-2.
    >> Share

  56. HAMILTON-REEVES JM, Bechtel MD, Hand LK, Schleper A, et al
    Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.
    Eur Urol. 2016;69:389-92.
    >> Share

    February 2016
  57. MMEJE CO, Guo CC, Shah JB, Navai N, et al
    Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    Eur Urol. 2016 Feb 24. pii: S0302-2838(16)00209.
    >> Share

  58. WILLIAMS SB, Kamat AM
    Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patien
    Eur Urol. 2016 Feb 10. pii: S0302-2838(16)00173.
    >> Share

  59. SYLVESTER R, Gontero P, Oddens J
    Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Surv
    Eur Urol. 2016 Feb 10. pii: S0302-2838(16)00175.
    >> Share

  60. SOAVE A, Rink M
    Words of Wisdom. Re: Vinflunine in Routine Clinical Practice for the Treatment of Advanced or Metastatic Urothelial Cell Carcinoma--Data from a Prospective, Multicenter Experience.
    Eur Urol. 2016;69:373-4.
    >> Share

  61. KAMAT AM, Urbauer DL
    Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guerin Therapy.
    Eur Urol. 2016;69:203.
    >> Share

  62. WITJES JA
    The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder Tumors.
    Eur Urol. 2016;69:245-6.
    >> Share

  63. ZUIVERLOON TC, Zwarthoff EC
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We Moving Forward?
    Eur Urol. 2016;69:201-2.
    >> Share

  64. SATKUNASIVAM R, Santomauro M, Chopra S, Plotner E, et al
    Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life.
    Eur Urol. 2016;69:247-53.
    >> Share

  65. KAMAT AM, Briggman J, Urbauer DL, Svatek R, et al
    Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin.
    Eur Urol. 2016;69:197-200.
    >> Share

  66. SYLVESTER RJ, Oosterlinck W, Holmang S, Sydes MR, et al
    Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carci
    Eur Urol. 2016;69:231-44.
    >> Share

    January 2016
  67. BIRKENKAMP-DEMTRODER K, Nordentoft I, Christensen E, Hoyer S, et al
    Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00058.
    >> Share

  68. ARENDS TJ, Nativ O, Maffezzini M, de Cobelli O, et al
    Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00057.
    >> Share

    December 2015
  69. KIM JH, Ku JH
    Re: Edwin E. Morales, Sonja Grill, Robert S. Svatek, et al. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.08.029.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01174.
    >> Share

  70. OHLMANN CH, Stockle M
    Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3
    Eur Urol. 2015;68:1104-5.
    >> Share

    November 2015
  71. RESNICK MJ
    Variation in Bladder Cancer Spending: A Global Call to Action.
    Eur Urol. 2015 Nov 19. pii: S0302-2838(15)01084.
    >> Share

    October 2015
  72. LEAL J, Luengo-Fernandez R, Sullivan R, Witjes JA, et al
    Economic Burden of Bladder Cancer Across the European Union.
    Eur Urol. 2015 Oct 24. pii: S0302-2838(15)01005.
    >> Share

    September 2015
  73. SONPAVDE G, Pond GR, Bellmunt J
    Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer - At What Cost? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.08.039: Combination Chemotherapy as a
    Eur Urol. 2015 Sep 23. pii: S0302-2838(15)00909.
    >> Share

  74. SONPAVDE G, Nix JW
    The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer.
    Eur Urol. 2015 Sep 20. pii: S0302-2838(15)00912.
    >> Share

  75. LA VECCHIA C
    Finasteride and Bladder Cancer.
    Eur Urol. 2015 Sep 10. pii: S0302-2838(15)00858.
    >> Share

  76. ROSE TL, Milowsky MI
    A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer - At What Cost?
    Eur Urol. 2015 Sep 4. pii: S0302-2838(15)00784.
    >> Share

  77. DOBRUCH J, Daneshmand S, Fisch M, Lotan Y, et al
    Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
    Eur Urol. 2015 Sep 4. pii: S0302-2838(15)00782.
    >> Share

    August 2015
  78. MORALES EE, Grill S, Svatek RS, Kaushik D, et al
    Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
    Eur Urol. 2015 Aug 27. pii: S0302-2838(15)00772.
    >> Share

  79. RENTSCH CA, Stenner F, Ruiz C, Bubendorf L, et al
    Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.
    Eur Urol. 2015 Aug 13. pii: S0302-2838(15)00709.
    >> Share

  80. BLACK PC
    Fine-tuning Risk Stratification for Non-Muscle-invasive Bladder Cancer.
    Eur Urol. 2015 Aug 6. pii: S0302-2838(15)00693.
    >> Share

    July 2015
  81. PLIMACK ER, Dunbrack RL, Brennan TA, Andrake MD, et al
    Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2015 Jul 31. pii: S0302-2838(15)00613.
    >> Share

  82. AINE M, Eriksson P, Liedberg F, Hoglund M, et al
    On Molecular Classification of Bladder Cancer: Out of One, Many.
    Eur Urol. 2015 Jul 24. pii: S0302-2838(15)00666.
    >> Share

  83. CAMBIER S, Sylvester RJ, Collette L, Gontero P, et al
    EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    Eur Urol. 2015 Jul 22. pii: S0302-2838(15)00556.
    >> Share

  84. FROEHNER M, Koch R, Heberling U, Novotny V, et al
    Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2015 Jul 17. pii: S0302-2838(15)00564.
    >> Share

  85. NGUYEN DP, Scherr DS
    Reply to Farshad Pourmalek, Hamidreza Abdi, and Peter C. Black's Letter to the Editor re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol.
    Eur Urol. 2015 Jul 14. pii: S0302-2838(15)00558.
    >> Share

  86. POURMALEK F, Abdi H, Black PC
    Re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.02.003.
    Eur Urol. 2015 Jul 13. pii: S0302-2838(15)00559.
    >> Share

  87. GOFRIT ON
    Re: Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Eur Urol. 2015;68:165-6.
    >> Share

  88. PALMA N, Morris JC, Ali SM, Ross JS, et al
    Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
    Eur Urol. 2015;68:168-70.
    >> Share

    June 2015
  89. DE MARTINO M, Lucca I, Mbeutcha A, Wiener HG, et al
    Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer.
    Eur Urol. 2015 Jun 29. pii: S0302-2838(15)00518.
    >> Share

  90. GIANNARINI G, Palumbo V, Ficarra V
    Words of Wisdom. Re: robotic intracorporeal orthotopic neobladder during radical cystectomy in 132 patients.
    Eur Urol. 2015;67:1191-2.
    >> Share

    April 2015
  91. HERR HW
    Reply from Author re: Peter C. Black. Narrowing the cystoscopy gap. Eur Urol 2015;67:609-10: A better transurethral resection--proved or not!
    Eur Urol. 2015;67:610-1.
    >> Share

  92. BLACK PC
    Narrowing the cystoscopy gap.
    Eur Urol. 2015;67:609-10.
    >> Share

  93. HERR HW
    Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.
    Eur Urol. 2015;67:605-8.
    >> Share

    March 2015
  94. CHAN KG, Guru K, Wiklund P, Catto J, et al
    Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel.
    Eur Urol. 2015;67:423-31.
    >> Share

  95. ARON M, Gill IS
    Robotic radical cystectomy: so far, so good--what next?
    Eur Urol. 2015;67:361-2.
    >> Share

  96. WILSON TG, Guru K, Rosen RC, Wiklund P, et al
    Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.
    Eur Urol. 2015;67:363-75.
    >> Share

  97. NOVARA G, Catto JW, Wilson T, Annerstedt M, et al
    Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy.
    Eur Urol. 2015;67:376-401.
    >> Share

  98. YUH B, Wilson T, Bochner B, Chan K, et al
    Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.
    Eur Urol. 2015;67:402-22.
    >> Share

    February 2015
  99. JONES RJ
    Making trials work in practice: please mind the gap.
    Eur Urol. 2015;67:250-1.
    >> Share

  100. VAN DER HEIJDEN MS, van Rhijn BW
    The molecular background of urothelial cancer: ready for action?
    Eur Urol. 2015;67:202-3.
    >> Share

  101. KIM PH, Cha EK, Sfakianos JP, Iyer G, et al
    Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Eur Urol. 2015;67:198-201.
    >> Share

    January 2015
  102. NAVAI N, Matin SF
    Words of wisdom. Re: A randomized trial of robot-assisted laparoscopic radical cystectomy.
    Eur Urol. 2015;67:173-4.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016